May 13, 2026
Cancer has long been called a silent killer, not because it lacks signs, but because those signs often arrive too late. For decades, oncology was dominated by a reactive model: patients presented with symptoms, received a diagnosis, and began treatment at an advanced stage when outcomes were already compromised. To...
Read More...
May 07, 2026
Multi4 Medical Received CE Mark - Moves Bladder Cancer Treatment from Operating Room to Outpatient Setting On 05 May 2026, the CE mark enabled the Multi4 System to be commercialized across Europe and represented a major advancement in urologic cancer care. The system introduced the world’s first all-in-one instr...
Read More...
Nov 12, 2025
The field of oncology and pathology hinges on one definitive step: the biopsy. Serving as the gold standard for diagnosing a vast majority of cancers and other diseases, the process of obtaining tissue samples has driven continuous technological innovation. The biopsy device market represents a vital sector within ...
Read More...
Jan 05, 2023
Inspira Technologies Signed Strategic OEM Agreement with Terumo Cardiovascular On December 27, 2023, Inspira Technologies, a ground breaking respiratory support technology company, announced that it has signed an exclusive OEM (Original Equipment Manufacturing) agreement with Terumo Cardiovascular, a division of...
Read More...
Dec 22, 2022
Medtronic Announced First Patient Enrolment for Hugo™ Robotic-Assisted Surgery System in US Clinical Trial On December 15, 2022, Medtronic, a global healthcare technology leader, announced that the first patient was enrolled in the Expand URO US clinical trial for the Hugo™ robotic-assisted surgery...
Read More...
Jun 09, 2022
Positive Results Report REVIAN RED System as a Possible Treatment for Central Centrifugal Cicatricical Alopeciain African American Women On June 02, 2022, REVIAN Inc., an aesthetic medical technology company focused on stimulating the body's natural processes in order to rejuvenate hair and skin with light relea...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper